TW202207971A - Ｉｌ－２融合多肽組成物及其製造與使用方法（二） - Google Patents

Ｉｌ－２融合多肽組成物及其製造與使用方法（二） Download PDF

Info

Publication number
TW202207971A
TW202207971A TW110116904A TW110116904A TW202207971A TW 202207971 A TW202207971 A TW 202207971A TW 110116904 A TW110116904 A TW 110116904A TW 110116904 A TW110116904 A TW 110116904A TW 202207971 A TW202207971 A TW 202207971A
Authority
TW
Taiwan
Prior art keywords
composition
polypeptide
citric acid
aqueous solution
specific embodiment
Prior art date
Application number
TW110116904A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗西斯卡 格佰米塔
塔雷克 席丹
Original Assignee
愛爾蘭商艾爾凱默斯醫藥愛爾蘭有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商艾爾凱默斯醫藥愛爾蘭有限公司 filed Critical 愛爾蘭商艾爾凱默斯醫藥愛爾蘭有限公司
Publication of TW202207971A publication Critical patent/TW202207971A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW110116904A 2020-05-11 2021-05-11 Ｉｌ－２融合多肽組成物及其製造與使用方法（二） TW202207971A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022860P 2020-05-11 2020-05-11
US63/022,860 2020-05-11

Publications (1)

Publication Number Publication Date
TW202207971A true TW202207971A (zh) 2022-03-01

Family

ID=78524880

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110116904A TW202207971A (zh) 2020-05-11 2021-05-11 Ｉｌ－２融合多肽組成物及其製造與使用方法（二）

Country Status (12)

Country Link
US (1) US20210395325A1 (https=)
EP (1) EP4149514A4 (https=)
JP (1) JP2023526024A (https=)
KR (1) KR20230008759A (https=)
CN (1) CN115867307A (https=)
AU (1) AU2021269585A1 (https=)
BR (1) BR112022022869A2 (https=)
CA (1) CA3172874A1 (https=)
IL (1) IL298064A (https=)
MX (1) MX2022014163A (https=)
TW (1) TW202207971A (https=)
WO (1) WO2021231319A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
EA202092926A3 (ru) * 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
MX2019013142A (es) * 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
MX2022004577A (es) * 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.

Also Published As

Publication number Publication date
EP4149514A1 (en) 2023-03-22
JP2023526024A (ja) 2023-06-20
MX2022014163A (es) 2023-02-22
AU2021269585A1 (en) 2022-12-15
BR112022022869A2 (pt) 2023-01-31
EP4149514A4 (en) 2024-06-26
US20210395325A1 (en) 2021-12-23
CA3172874A1 (en) 2021-11-18
CN115867307A (zh) 2023-03-28
KR20230008759A (ko) 2023-01-16
WO2021231319A1 (en) 2021-11-18
IL298064A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
EP2676677B1 (en) Highly concentrated anti-cd40 antibody pharmaceutical preparation
US11241498B2 (en) Room temperature stable lyophilized protein
JP5537425B2 (ja) 凍結乾燥抗真菌組成物
EP2385825B1 (en) Factor viii formulations
ES2775698T3 (es) Procedimiento de producción de gránulos liofilizados que comprenden el factor VIII
US20260049132A1 (en) Anti-connexin antibody formulations
RS55772B1 (sr) Stabilizacija fsh
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
EP4374874A1 (en) Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof
JP2022003101A (ja) 第Ｘａ因子解毒剤の凍結乾燥製剤
KR20200033265A (ko) Il-15 단백질 복합체 약학 조성물 및 이의 용도
MD3791860T2 (ro) Formulare de gonadotropină lichidă stabilă
EP3060256B1 (en) A novel stable formulation
TW202207971A (zh) Ｉｌ－２融合多肽組成物及其製造與使用方法（二）
TW202207970A (zh) Ｉｌ－２融合多肽組成物及其製造與使用方法（一）
AU2020304649B2 (en) Composition and methods for stabilizing liquid protein formulations
CN115998690B (zh) 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
KR20240072273A (ko) 접합체 약물 제제, 이의 제조 방법 및 용도
KR20230146515A (ko) 개선된 동결건조 제형